California Medical Cannabis and the June 26 DEA Deadline

A federal rescheduling order has, for the first time, drawn a sharp legal line between California’s medicinal and adult-use cannabis markets. For state-licensed medical operators, a narrow registration window closes on June 26, 2026, and the choices made this week carry consequences that extend well beyond a single filing.

By the Baghoomian Law team

The Schedule III Order and What It Actually Covers

On April 23, 2026, the U.S. Department of Justice issued a final order rescheduling certain cannabis from Schedule I to Schedule III of the Controlled Substances Act, with the rule published in the Federal Register on April 28, 2026. The reach of that order is narrower than the headlines suggest. It moves FDA-approved drug products containing marijuana, and marijuana that is subject to a qualifying state-issued medical marijuana license, into Schedule III. Cannabis that is neither part of an FDA-approved drug product nor covered by a state medical license remains in Schedule I.

For California, that distinction matters enormously. The state runs a single regulated market under the Medicinal and Adult-Use Cannabis Regulation and Safety Act, but the federal order recognizes only the medicinal side. Adult-use (“A”) cannabis remains a Schedule I substance as a matter of federal law, while medicinal (“M”) product tied to a qualifying state license is now treated as Schedule III. The result is a bifurcated federal landscape layered on top of a unified state one, and operators who hold combined A and M designations now sit on both sides of that federal line at the same time. The rescheduling action is published in the Federal Register (federalregister.gov, document 2026-08176).

The June 26 Registration Window

The most time-sensitive consequence is a deadline. The DEA began accepting applications from state-licensed medical cannabis businesses on April 29, 2026, through its Medicinal Marijuana Dispensary Registration Portal (mmapplication.diversion.dea.gov). Operators who submit within the priority window receive expedited review, and applicants who file in time may continue operating under their state-issued licenses while their application is pending. As widely reported across the industry, that window closes on June 26, 2026, with a non-refundable annual application fee of $794.

The practical significance of filing early is not merely administrative. As industry advisors have noted, federal registration is better understood as a comprehensive audit than as a routine form. According to mg Magazine (mgmagazine.com), the DEA will expect operators to readily produce corporate ownership disclosures, facility blueprints, zoning and local approvals, security and surveillance protocols, inventory and chain-of-custody procedures, and employee training records. Businesses that have built compliance programs to satisfy California regulators are not starting from zero, but the consistency, accessibility, and completeness of those records take on new weight under federal scrutiny.

A second deadline sits just behind the first. The DEA has scheduled an expedited hearing beginning June 29, 2026, to consider whether marijuana as a whole, rather than only FDA-approved and state-licensed medical product, should be reclassified to Schedule III. That proceeding remains pending, and its outcome is genuinely uncertain. Operators should treat the current order as the governing rule today while recognizing that the broader framework is still being contested.

How California Is Responding: Form 27 and Designation Changes

California’s Department of Cannabis Control has moved to align its licensing process with the new federal reality. On its federal rescheduling resources page (cannabis.ca.gov), the DCC explains that it has streamlined the process for changing a license designation. Cultivation licensees no longer need to wait until renewal to request a change to their adult-use or medicinal designation, and the Department has removed the requirement for new local authorization for two specific kinds of requests: changing a license to M-designation only, or adding an M-designation to an existing A-designation license.

All licensees can now request a change of designation at any time by submitting Form 27: Notifications and Requests to Modify a License, which must be filed by the designated responsible party using the email address listed for that party in the license record. The DCC is emphatic on one point that operators sometimes miss in the rush to react: a licensee must continue operating under its current designation until the change has actually been approved. Submitting the form does not, by itself, change a license’s status.

The Emergency Split-License Pathway

Beyond the streamlined designation changes, the DCC has launched an emergency rulemaking that goes a step further. Designated DCC-2026-03-E: Modifications to A and M Designation, the action would allow existing licensees who currently hold a single license carrying both a medicinal and an adult-use designation to instead be issued separate M and A licenses, through an expedited process. Notably, the proposed regulations would also permit those separate licenses to be issued to a different legal entity from the one holding the existing license, provided certain conditions are met, while imposing conditions designed to preserve the integrity of the existing licensing system. The Department provided notice of the proposed emergency action on May 18, 2026, and the Office of Administrative Law accepted public comment from May 27 through May 31, 2026.

For operators, the appeal of a structural split is clear. Separating the medicinal business into its own license, and potentially its own entity, allows it to pursue federal registration as a Schedule III medical operation while the adult-use business continues to operate under state law on the Schedule I side of the line. That kind of restructuring, however, raises a thicket of questions about ownership disclosures, financing arrangements, local approvals, lease and premises issues, and tax structure that should be worked through deliberately rather than under deadline pressure.

The 280E Question

One of the most consequential financial implications of rescheduling concerns Internal Revenue Code Section 280E, which disallows ordinary business deductions for taxpayers trafficking in Schedule I or Schedule II controlled substances. Because Schedule III falls outside that provision, the rescheduling order has been read to relieve holders of qualifying state medical licenses from 280E’s deduction disallowance, a change that could materially affect profitability and valuation for medical operators. This is a significant development, but it is also one where the details govern. The scope of the relief, its timing, and how it interacts with an operator’s particular corporate structure are fact-specific questions, and as industry coverage has cautioned, individual tax treatment still deserves review by qualified tax counsel before any business changes its filings or its financial planning.

What This Means for California Operators

The immediate takeaway is that the June 26 window rewards preparation, not improvisation. Operators who hold or plan to hold a qualifying M license should be confirming that their state licenses, ownership records, security and inventory controls, standard operating procedures, and traceability data are current, internally consistent, and quickly retrievable, because those are precisely the materials federal registration will test. Operators weighing whether to split their A and M operations, change a designation through Form 27, or restructure into separate entities should map how each path interacts with local authorization, financing, premises arrangements, and tax exposure before filing anything. And every operator should keep in mind the DCC’s reminder that a license designation does not change until the Department approves the request, and that adult-use activity remains federally Schedule I regardless of any state-level change.

This is a moment that genuinely blends federal controlled-substances law, California licensing regulation, and tax planning, and the right answer depends heavily on each operator’s structure and goals. If you are evaluating whether and how to pursue DEA registration, change a license designation, or restructure your medicinal and adult-use operations, the team at Baghoomian Law advises California cannabis businesses on licensing strategy and regulatory compliance and would welcome the opportunity to help you think through your options. Contact us to discuss your situation.

This post is for informational purposes only and does not constitute legal advice. Consult licensed counsel for advice on your specific situation.